Mutation Trajectory of Omicron SARS-CoV-2 Virus, Measured by Principal Component Analysis
Abstract
:1. Introduction
2. Materials and Methods
2.1. PCA
2.2. PCA for Sequencing Data
2.3. Data Curation
2.4. 3 D Structure of Proteins
3. Results
3.1. Mutations Observed from Nucleotide Sequence
3.2. Sites of Mutation in the Genome
3.3. Mutations Observed in Spike Protein
3.4. Mutated Sites in Spike Proteins in the 3D Structure
4. Discussion
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- WHO. Coronavirus Disease (COVID-19) Pandemic. Available online: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 (accessed on 23 May 2023).
- Konishi, T. Mutations in SARS-CoV-2 are on the increase against the acquired immunity. PLoS ONE 2022, 17, e0271305. [Google Scholar] [CrossRef] [PubMed]
- Wolf, J.M.; Wolf, L.M.; Bello, G.L.; Maccari, J.G.; Nasi, L.A. Molecular evolution of SARS-CoV-2 from December 2019 to August 2022. J. Med. Virol. 2023, 95, e28366. [Google Scholar] [CrossRef]
- Zhang, H.; Lv, P.; Jiang, J.; Liu, Y.; Yan, R.; Shu, S.; Hu, B.; Xiao, H.; Cai, K.; Yuan, S.; et al. Advances in developing ACE2 derivatives against SARS-CoV-2. Lancet Microbe. 2023, 4, e369–e378. [Google Scholar] [CrossRef] [PubMed]
- Cao, Y.; Jian, F.; Wang, J.; Yu, Y.; Song, W.; Yisimayi, A.; Wang, J.; An, R.; Chen, X.; Zhang, N.; et al. Imprinted SARS-CoV-2 humoral immunity induces convergent Omicron RBD evolution. Nature 2023, 614, 521–529. [Google Scholar] [CrossRef] [PubMed]
- Ito, J.; Suzuki, R.; Uriu, K.; Itakura, Y.; Zahradnik, J.; Kimura, K.T.; Deguchi, S.; Wang, L.; Lytras, S.; Tamura, T.; et al. Convergent evolution of SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1.1 variant. Nat. Commun. 2023, 14, 2671. [Google Scholar] [CrossRef]
- Wang, Q.; Iketani, S.; Li, Z.; Liu, L.; Guo, Y.; Huang, Y.; Bowen, A.D.; Liu, M.; Wang, M.; Yu, J.; et al. Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants. Cell 2023, 186, 279–286.e8. [Google Scholar] [CrossRef] [PubMed]
- Yang, S.; Yu, Y.; Xu, Y.; Jian, F.; Song, W.; Yisimayi, A.; Wang, P.; Wang, J.; Liu, J.; Yu, L.; et al. Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure. Lancet Infect. Dis. 2024, 24, e70–e72. [Google Scholar] [CrossRef]
- Jian, F.; Feng, L.; Yang, S.; Yu, Y.; Wang, L.; Song, W.; Yisimayi, A.; Chen, X.; Xu, Y.; Wang, P.; et al. Convergent evolution of SARS-CoV-2 XBB lineages on receptor-binding domain 455–456 synergistically enhances antibody evasion and ACE2 binding. PLoS Pathog. 2023, 19, e1011868. [Google Scholar] [CrossRef] [PubMed]
- Yao, Z.; Zhang, L.; Duan, Y.; Tang, X.; Lu, J. Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein. J. Infect. 2024, 88, 106121. [Google Scholar] [CrossRef]
- Magazine, N.; Zhang, T.; Wu, Y.; McGee, M.C.; Veggiani, G.; Huang, W. Mutations and Evolution of the SARS-CoV-2 Spike Protein. Viruses 2022, 14, 640. [Google Scholar] [CrossRef]
- Focosi, D.; Quiroga, R.; McConnell, S.; Johnson, M.C.; Casadevall, A. Convergent Evolution in SARS-CoV-2 Spike Creates a Variant Soup from Which New COVID-19 Waves Emerge. Int. J. Mol. Sci. 2023, 24, 2264. [Google Scholar] [CrossRef]
- Zabidi, N.Z.; Liew, H.L.; Farouk, I.A.; Puniyamurti, A.; Yip, A.J.W.; Wijesinghe, V.N.; Low, Z.Y.; Tang, J.W.; Chow, V.T.K.; Lal, S.K. Evolution of SARS-CoV-2 Variants: Implications on Immune Escape, Vaccination, Therapeutic and Diagnostic Strategies. Viruses 2023, 15, 944. [Google Scholar] [CrossRef] [PubMed]
- Zahradník, J.; Nunvar, J.; Schreiber, G. Perspectives: SARS-CoV-2 Spike Convergent Evolution as a Guide to Explore Adaptive Advantage. Front. Cell. Infect. Microbiol. 2022, 12, 748948. [Google Scholar] [CrossRef]
- WHO. Tracking SARS-CoV-2 Variants. Available online: https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/ (accessed on 7 April 2024).
- Konishi, T. Re-evaluation of the evolution of influenza H1 viruses using direct PCA. Sci. Rep. 2019, 9, 19287. [Google Scholar] [CrossRef]
- R Core Team. R: A Language and Environment for Statistical Computing; R Foundation for Statistical Computing: Vienna, Austria, 2020; Available online: https://cran.r-project.org/ (accessed on 7 April 2024).
- Elbe, S.; Buckland-Merrett, G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob. Chall. 2017, 1, 33–46. [Google Scholar] [CrossRef]
- Wright, E.S. DECIPHER: Harnessing local sequence context to improve protein multiple sequence alignment. BMC Bioinform. 2015, 16, 322. [Google Scholar] [CrossRef]
- Yan, R.H.; Zhang, Y.Y.; Li, Y.N.; Ye, F.F.; Guo, Y.Y.; Xia, L.; Zhong, X.Y.; Chi, X.M.; Zhou, Q. S Protein of SARS-CoV-2 in the Active Conformation. Available online: https://www.wwpdb.org/pdb?id=pdb_00007dwz (accessed on 7 April 2024).
- Berman, H.M.; Westbrook, J.; Feng, Z.; Gilliland, G.; Bhat, T.N.; Weissig, H.; Shindyalov, I.N.; Bourne, P.E. The Protein Data Bank. Nucleic Acids Res. 2000, 28, 235–242. [Google Scholar] [CrossRef]
- Heo, C.-K.; Lim, W.-H.; Yang, J.; Son, S.; Kim, S.J.; Kim, D.-J.; Poo, H.; Cho, E.-W. Novel S2 subunit-specific antibody with broad neutralizing activity against SARS-CoV-2 variants of concern. Front. Immunol. 2023, 14, 1307693. [Google Scholar] [CrossRef] [PubMed]
- Murdoch, D.; Adler, D.; Nenadic, O.; Urbanek, S.; Chen, M.; Gebhardt, A.; Bolker, B.; Csardi, G.; Strzelecki, A.; Senger, A.; et al. rgl: 3D Visualization Using OpenGL. Available online: https://cran.r-project.org/web/packages/rgl/index.html (accessed on 7 April 2024).
- Konishi, T. Continuous mutation of SARS-CoV-2 during migration via three routes. PeerJ 2022, 10, e12681. [Google Scholar] [CrossRef] [PubMed]
- Konishi, T. A Comparative Analysis of COVID-19 Response Measures and Their Impact on Mortality Rate. COVID 2024, 4, 130–150. [Google Scholar] [CrossRef]
- Konishi, T. COVID-19 Epidemics Monitored Through the Logarithmic Growth Rate and SIR Model. J. Clin. Immunol. Microbiol. 2022, 3, 1–45. [Google Scholar] [CrossRef]
- Suryamohan, K.; Diwanji, D.; Stawiski, E.W.; Gupta, R.; Miersch, S.; Liu, J.; Chen, C.; Jiang, Y.-P.; Fellouse, F.A.; Sathirapongsasuti, J.F.; et al. Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2. Commun. Biol. 2021, 4, 475. [Google Scholar] [CrossRef] [PubMed]
- Sano, E.; Deguchi, S.; Sakamoto, A.; Mimura, N.; Hirabayashi, A.; Muramoto, Y.; Noda, T.; Yamamoto, T.; Takayama, K. Modeling SARS-CoV-2 infection and its individual differences with ACE2-expressing human iPS cells. iScience 2021, 24, 102428. [Google Scholar] [CrossRef] [PubMed]
- Buchan, S.A.; Chung, H.; Brown, K.A.; Austin, P.C.; Fell, D.B.; Gubbay, J.B.; Nasreen, S.; Schwartz, K.L.; Sundaram, M.E.; Tadrous, M.; et al. Estimated Effectiveness of COVID-19 Vaccines Against Omicron or Delta Symptomatic Infection and Severe Outcomes. JAMA Netw. Open 2022, 5, e2232760. [Google Scholar] [CrossRef] [PubMed]
- Hansen, C.H.; Schelde, A.B.; Moustsen-Helm, I.R.; Emborg, H.-D.; Krause, T.G.; Mølbak, K.; Valentiner-Branth, P.; on behalf of the Infectious Disease Preparedness Group at Statens Serum Institut. Vaccine effectiveness against SARS-CoV-2 infection with the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 vaccination series: A Danish cohort study. medRxiv 2021. [Google Scholar] [CrossRef]
- Pérez-Then, E.; Lucas, C.; Monteiro, V.S.; Miric, M.; Brache, V.; Cochon, L.; Vogels, C.B.F.; Malik, A.A.; De la Cruz, E.; Jorge, A.; et al. Neutralizing antibodies against the SARS-CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2 booster vaccination. Nat. Med. 2022, 28, 481–485. [Google Scholar] [CrossRef] [PubMed]
- Gao, F.X.; Wu, R.X.; Shen, M.Y.; Huang, J.J.; Li, T.T.; Hu, C.; Luo, F.Y.; Song, S.Y.; Mu, S.; Hao, Y.N.; et al. Extended SARS-CoV-2 RBD booster vaccination induces humoral and cellular immune tolerance in mice. iScience 2022, 25, 105479. [Google Scholar] [CrossRef] [PubMed]
- Gruell, H.; Vanshylla, K.; Tober-Lau, P.; Hillus, D.; Schommers, P.; Lehmann, C.; Kurth, F.; Sander, L.E.; Klein, F. mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med. 2022, 28, 477–480. [Google Scholar] [CrossRef] [PubMed]
- Harvey, W.T.; Carabelli, A.M.; Jackson, B.; Gupta, R.K.; Thomson, E.C.; Harrison, E.M.; Ludden, C.; Reeve, R.; Rambaut, A.; Peacock, S.J.; et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat. Rev. Microbiol. 2021, 19, 409–424. [Google Scholar] [CrossRef] [PubMed]
- Irrgang, P.; Gerling, J.; Kocher, K.; Lapuente, D.; Steininger, P.; Habenicht, K.; Wytopil, M.; Beileke, S.; Schäfer, S.; Zhong, J.; et al. Class switch toward noninflammatory, spike-specific IgG4 antibodies after repeated SARS-CoV-2 mRNA vaccination. Sci. Immunol. 2023, 8, eade2798. [Google Scholar] [CrossRef]
- Kiszel, P.; Sík, P.; Miklós, J.; Kajdácsi, E.; Sinkovits, G.; Cervenak, L.; Prohászka, Z. Class switch towards spike protein-specific IgG4 antibodies after SARS-CoV-2 mRNA vaccination depends on prior infection history. Sci. Rep. 2023, 13, 13166. [Google Scholar] [CrossRef]
- Uversky, V.N.; Redwan, E.M.; Makis, W.; Rubio-Casillas, A. IgG4 Antibodies Induced by Repeated Vaccination May Generate Immune Tolerance to the SARS-CoV-2 Spike Protein. Vaccines 2023, 11, 991. [Google Scholar] [CrossRef] [PubMed]
- Konishi, T. SARS-CoV-2 mutations among minks show reduced lethality and infectivity to humans. PLoS ONE 2021, 16, e0247626. [Google Scholar] [CrossRef] [PubMed]
- National Institute of Infectious Diseases, Japan. New Coronavirus Infectious Disease Surveillance News/Weekly Report: Understand the Status of Outbreak Trends. Available online: https://www.niid.go.jp/niid/ja/2019-ncov/2484-idsc/12015-covid19-surveillance-report.html (accessed on 7 April 2024).
- Katella, K. 3 Things to Know About JN.1, the New Coronavirus Strain. Available online: https://www.yalemedicine.org/news/jn1-coronavirus-variant-covid (accessed on 7 April 2024).
- Kaku, Y.; Okumura, K.; Padilla-Blanco, M.; Kosugi, Y.; Uriu, K.; Hinay, A.A., Jr.; Chen, L.; Plianchaisuk, A.; Kobiyama, K.; Ishii, K.J.; et al. Virological characteristics of the SARS-CoV-2 JN.1 variant. Lancet Infect. Dis. 2024, 24, e82. [Google Scholar] [CrossRef] [PubMed]
- Sohail, M.S.; Ahmed, S.F.; Quadeer, A.A.; McKay, M.R. Cross-Reactivity Assessment of Vaccine-Derived SARS-CoV-2 T Cell Responses against BA.2.86 and JN.1. Viruses 2024, 16, 473. [Google Scholar] [CrossRef] [PubMed]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Konishi, T.; Takahashi, T. Mutation Trajectory of Omicron SARS-CoV-2 Virus, Measured by Principal Component Analysis. COVID 2024, 4, 571-581. https://doi.org/10.3390/covid4040038
Konishi T, Takahashi T. Mutation Trajectory of Omicron SARS-CoV-2 Virus, Measured by Principal Component Analysis. COVID. 2024; 4(4):571-581. https://doi.org/10.3390/covid4040038
Chicago/Turabian StyleKonishi, Tomokazu, and Toa Takahashi. 2024. "Mutation Trajectory of Omicron SARS-CoV-2 Virus, Measured by Principal Component Analysis" COVID 4, no. 4: 571-581. https://doi.org/10.3390/covid4040038